CPT1A and neoplasm: We observed that TAMs from mice reconstituted with Cpt1a-deficient bone marrows expressed lower levels of Cpt1a (Extended Data Fig. 3h), and FGK45 treatments failed to suppress tumor growth and tumor burden (Fig. 2g,h).